Evaluation of aztreonam and ampicillin vs. amikacin and ampicillin for treatment of neonatal bacterial infections

M. A. Umana, C. M. Odio, E. Castro, J. L. Salas, G. H. McCracken

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

In a prospective randomized, open study we evaluated aztreonam (AZ) for treatment of neonatal bacterial infections. There were 147 patients enrolled in the study; 75 received AZ and ampicillin (AMP) and 72 amikacin (AM) and AMP (conventional therapy). Twenty-eight AZ/AMP-treated patients and 32 conventionally treated patients had bacteriologically documented infections caused by gram–negative enteric bacilli or Pseudomonas species. Treatment groups were comparable in age, clinical status, and type and severity of underlying disease at the time of enrollment. Bronchopneumonia and infections caused by Pseudomonas species oc.

Original languageEnglish (US)
Pages (from-to)175-180
Number of pages6
JournalPediatric Infectious Disease Journal
Volume9
Issue number3
DOIs
StatePublished - Mar 1990

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Evaluation of aztreonam and ampicillin vs. amikacin and ampicillin for treatment of neonatal bacterial infections'. Together they form a unique fingerprint.

  • Cite this